Results 41 to 50 of about 8,307 (166)

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

Membranoproliferative Glomerulonephritis Associated with Nivolumab Therapy

Case Reports in Nephrology, 2020
Nivolumab is an immune checkpoint inhibitor that targets programmed death-1 on T cells and is designed to amplify an immunologic reaction against cancer cells.
Jessica Cruz-Whitley, Nolan Giehl, Kuang-Yu Jen, Brian Young   +3 more
doaj   +1 more source

Biomarkers for Early Detection of Diabetic Kidney Disease in Pediatric and Adolescent Populations: A Narrative Review

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Diabetic nephropathy is among the most critical long‐term complications linked to diabetes, substantially influencing both morbidity and mortality. Although it was once largely associated with adults, diabetic kidney disease (DKD) has now become a leading source of kidney complications among children worldwide.
Iran Malekzadeh, Narges Falsafi, Mohammad Nazemi, Hanie Taherkhani, Mahboube Bahroudi, Asim Abbas, Mastaneh Moghtaderi   +6 more
wiley   +1 more source

The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis

BMC Nephrology, 2020
Background C3 glomerulonephritis is a recently described entity with heterogeneous histopathological features. This study was conducted to assess the effect of reclassification of C3 glomerulopathies on renal outcomes, mortality, and response to therapy.
P. Puri, G. D. Walters, M. N. Fadia, M. Konia, K. A. Gibson, S. H. Jiang   +5 more
doaj   +1 more source

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

British Journal of Pharmacology, Volume 183, Issue 11, Page 2874-2889, June 2026.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva, Guido Junge, Kenneth Kulmatycki, Robert Schmouder, Anna Schubart, Marie‐Anne Valentin   +5 more
wiley   +1 more source

A Framework for Emergency Department–Integrated Hepatitis C Test‐and‐Treat in the United States

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Despite the availability of curative, direct‐acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align
Saeed S. Graham
wiley   +1 more source

Immunotactoid glomerulopathy and chronic lymphocytic leukemia: The need for a multidisciplinary approach

eJHaem, 2023
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in western countries. The association between CLL and glomerular disease (GD) is rare. The most frequent GD associated with CLL is membranoproliferative membranous glomerulonephritis (
Angela Rago, Laura Pettorini, Alessandro Andriani, Tommaso Caravita di Toritto   +3 more
doaj   +1 more source

Late Presentation of de Novo Proliferative Glomerulonephritis With Monoclonal IgG Deposits in a Renal Allograft: A Rare Case With an Unusual Clinical Course

Nephrology, Volume 31, Issue 6, June 2026.
ABSTRACT Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a form of monoclonal gammopathy of renal significance (MGRS) in which monoclonal immunoglobulin deposits are found within the glomerulus, without involvement of other renal compartments.
Hayley J. Duxbury, David A. Brown, Adrian Y. S. Lee, Germaine Wong, Fiona Kwok, Seethalakshmi Viswanathan   +5 more
wiley   +1 more source

A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits That Showed Predominantly Membranous Features

Case Reports in Nephrology, 2017
In 2004, the novel category of monoclonal IgG deposition disease has been proposed and termed “proliferative glomerulonephritis with monoclonal IgG deposits” (PGNMID). This disease is characterized by membranoproliferative glomerulonephritis and staining
Homare Shimohata, Kentaro Ohgi, Hiroshi Maruyama, Yasunori Miyamoto, Mamiko Takayashu, Kouichi Hirayama, Masaki Kobayashi   +6 more
doaj   +1 more source

Membranoproliferative Glomerulonephritis and Persistent Hypocomplementaemia [PDF]

BMJ, 1970
The clinical, laboratory, and histological findings of 50 patients with membranoproliferative glomerulonephritis are described. Three-quarters of the patients, who were mostly older children and young adults, presented clinically with a mixture of "nephritic" and "nephrotic" symptoms; the remaining quarter had no symptoms and were diagnosed after the ...
J S, Cameron, E F, Glasgow, C S, Ogg, R H, White   +3 more
openaire   +2 more sources